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Abstract
Background: The scale-up of antiretroviral treatment (ART) programmes has seen HIV/AIDS transition to a chronic
condition characterised by high rates of comorbidity with tuberculosis, non-communicable diseases (NCDs) and mental
health disorders. Depression is one such disorder that is associated with higher rates of non-adherence, progression to
AIDS and greater mortality. Detection and treatment of comorbid depression is critical to achieve viral load suppression
in more than 90% of those on ART and is in line with the recent 90-90-90 Joint United Nations Programme on HIV/AIDS
(UNAIDS) targets. The CobALT trial aims to provide evidence on the effectiveness and cost-effectiveness of scalable
interventions to reduce the treatment gap posed by the growing burden of depression among adults on lifelong ART.
Methods: The study design is a pragmatic, parallel group, stratified, cluster randomised trial in 40 clinics across two rural
districts of the North West Province of South Africa. The unit of randomisation is the clinic, with outcomes measured
among 2000 patients on ART who screen positive for depression using the Patient Health Questionnaire (PHQ-9). Control
group clinics are implementing the South African Department of Health’s Integrated Clinical Services Management model,
which aims to reduce fragmentation of care in the context of rising multimorbidity, and which includes training in the
Primary Care 101 (PC101) guide covering communicable diseases, NCDs, women’s health and mental disorders. In
intervention clinics, we supplemented this with training specifically in the mental health components of PC101 and
clinical communications skills training to support nurse-led chronic care. We strengthened the referral pathways through
the introduction of a clinic-based behavioural health counsellor equipped to provide manualised depression counselling
(eight sessions, individual or group), as well as adherence counselling sessions (one session, individual). The co-primary
patient outcomes are a reduction in PHQ-9 scores of at least 50% from baseline and viral load suppression rates
measured at 6 and 12 months, respectively.
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Discussion: The trial will provide real-world effectiveness of case detection and collaborative care for depression
including facility-based counselling on the mental and physical outcomes for people on lifelong ART in resource-
constrained settings.
Trial registration: ClinicalTrials.gov (NCT02407691) registered on 19 March 2015; Pan African Clinical Trials
Registry (201504001078347) registered on 19/03/2015; South African National Clinical Trials Register (SANCTR)
(DOH-27-0515-5048) NHREC number 4048 issued on 21/04/2015.
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Background
In late 2014, the Joint United Nations Programme on
HIV/AIDS set the ambitious 90-90-90 targets to renew ef-
forts required to achieve an AIDS-free generation, stipu-
lating 90% of people with HIV diagnosed, 90% of those
who know their HIV-positive status on antiretroviral treat-
ment (ART), and 90% of people on ART virally suppressed
by 2020 [1]. Current debate regarding the targets has con-
cerned the funding required and the shape of the inter-
ventions needed to be scaled in order to meet them [2].
These include focusing on key populations such as young
women [3, 4], the introduction of universal test and treat
programmes [5], and integration with related programmes
including those for tuberculosis, maternal and child
health, and sexually transmitted infections [6]. The inter-
section between HIV, non-communicable diseases (NCDs)
and mental health is notably absent from this discourse,
despite recent evidence demonstrating the scale and con-
sequences of the collision of these respective epidemics.
Increased incidence of hypertension, cardiovascular events
and depression are well documented in people living with
HIV and are two- to five-fold more common than in the
general population [7–10]. This is against a backdrop
where the 2013 Global Burden of Disease Study showed
that major depressive disorder is emerging as a leading
cause of Years Lived with Disability globally, secondary
only to ischaemic heart disease, and among the top three
causes of Years Lived with Disability in as many as 146
countries [11, 12].
Depression prevalence varies widely across HIV pop-
ulations [13, 14]. Among those who are depressed, poor
adherence is associated with acute life event threats
and stresses, which predicts a decline in treatment
adherence for HIV [14, 15]. These findings suggest that
depression-prone HIV-infected individuals in the con-
text of life stress are more likely to have lapses in ad-
herence to treatment and may potentially compromise
attainment of the 90-90-90 targets, especially as it per-
tains to adherence. This is particularly troubling where
adherence to ART is paramount to achieving sustained
virologic suppression, better clinical outcomes and
avoiding the emergence of drug resistance [13].
Studies from high-income countries suggest that
pharmacological and psychological treatments for de-
pression and anxiety are equally effective in people liv-
ing with HIV as they are in people not infected with
HIV [10, 16]. However, studies from low- and middle-
income countries (LMICs) are limited. In Uganda,
Zimbabwe and Cameroon, pilot studies have shown
that counselling [17, 18] or antidepressants [19] are
effective in reducing depression scores. Additionally,
counselling interventions have also been found to im-
prove ART adherence [20], CD4 cell count and viral
load suppression [19]. The studies from LMICs, how-
ever, were relatively small, involving around 40 to 320
participants and had a short duration of follow-up of
only a few weeks to 4 months.
South Africa has the unfortunate distinction of having
the highest number of people living with HIV/AIDS of any
single country in the world. The country is home to 0.7%
of the world’s population, yet 17% of all people infected
with HIV live here [21]. After a much-publicised delay in
rolling out ART, the South African National Health De-
partment has now made considerable progress and runs
the world’s largest treatment programme with roughly 3.4
million of the approximately 7 million people infected be-
ing on treatment [22]. The initial estimates of viral sup-
pression rates were encouraging [23, 24], but have not
been sustained as the programme is scaled up and people
come to terms with the challenges of life-long treatment
for sustained viral suppression, despite feeling clinically
considerably better [25, 26]. The introduction, in 2009, of a
fixed dose ART combination (FDC) has reduced pill bur-
den substantively, comprising one tablet once a day, and
approximately 90% of all people on ART in South Africa
are receiving this. The South African programme has
adopted a public health approach to monitoring, with viral
loads recommended at 6 and 12 months after initiation
and yearly thereafter. Over 4 million viral loads were mea-
sured in 2015; of the 75% of people in which a viral load
test was performed in the previous 12 months, 78% were
virally suppressed [27]. Heterogeneity is usual, with rates of
viral load suppression varying between 69% and 82% across
provinces. Interventions to strengthen adherence include
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spaced and fast lane appointment systems, adherence clubs
and central chronic medicine dispensing and distribution.
However, there has been limited attention paid to identify-
ing and addressing underlying depression, which may be a
major contributing factor to declining viral suppression
rates [28].
This is consistent with the gap in mental healthcare
provision in general. The South African Stress and Health
study completed in 2003–2004, in which approximately
4500 adults were surveyed from communities in all nine
provinces, found a lifetime prevalence of mental disorders
of 30% and a 12 month prevalence of 17%. However, only
a quarter of people with a 12-month diagnosis of mental
disorder reported receiving any treatment from any source
[29–31]. More recently, data from one of our previous tri-
als undertaken in rural areas of the Western Cape showed
that this gap had not narrowed; indeed, only 614 of 2466
patients who screened positive for depressive symptoms
in primary care clinics reported any treatment (25%) and
less than half of these reported treatment with antidepres-
sants (294/2466, 12%) [32].
On the plus side, in 2013, the national Department of
Health adopted a new national Mental Health Policy
Framework, which, among other things, provides for the
strengthening of mental health service delivery through
primary care [33]. Mental health has also been included
in an integrated approach to people living with chronic
conditions, called the Integrated Clinical Services Man-
agement (ICSM) programme, and being introduced by
the South African Department of Health [34]. The ICSM
aims to promote a one-stop comprehensive service for
people with multiple chronic and/or acute diseases,
whether communicable or not, at the primary care level
[35, 36]. One of its key elements is PC101, developed by
the Knowledge Translation Unit at the University of
Cape Town Lung Institute, which comprises a concise
(101-page) guide of algorithms and checklists covering
the main symptoms and chronic conditions that present
in primary care [37]. Twelve onsite interactive training
sessions in case scenarios are used to familiarise health
workers with the content of the guide and to promote
their use of it during consultations. Randomised con-
trolled trials (RCTs) of PC101 and its precursors have
shown positive impacts on a range of quality of care in-
dicators, mainly in the area of communicable diseases,
but no effect on depression case detection or treatment
[38–40]. Process evaluation suggests that training alone
is insufficient to overcome structural health system bar-
riers presented by the limited availability of counselling
and referral pathways, and restriction of antidepressant
prescribing to doctors who are in short supply.
The Programme for Improving Mental Health Care
(PRIME) [41] in South Africa has been working in one
of the pilot districts for the ICSM for the past 4 years to
develop and evaluate the feasibility of an integrated col-
laborative care model for priority mental disorders, in-
cluding depression. The model includes strengthening of
the mental health component of the PC101 training and
referral pathways for management of common mental
disorders [42]. These include the use of facility-based
community health worker-level behavioural health coun-
sellors to provide manualised counselling for chronic
care patients with depression that has shown promise in
a small pilot trial [43]; strengthened referral pathways
for initiation of antidepressant medications by primary
healthcare doctors; and onward referral to mental health
specialists for more severe and treatment resistant de-
pression. In addition, systems strengthening innovations
to support these efforts have been introduced through
the Emerald (emerging mental health systems in LMICs)
programme [44], including clinical communication skills
for nurse-led chronic care and a strengthened employee
assistance programme for primary healthcare providers
experiencing emotional problems and burn-out.
Development of the strengthened mental health inter-
vention has been iterative, guided by the Medical Research
Council framework for the development of complex inter-
ventions [45] and refined during two successive pilots,
with the first in a single clinic and the second in a further
three clinics. The resultant intervention is being scaled up
to 10 clinics in the Dr Kenneth Kaunda District and a fur-
ther 10 clinics in the adjacent Bojanala district during the
period 2014–2017. The intervention targets depression
comorbid with all common chronic conditions being
managed in primary care. A pair of trials is evaluating the
effects of this intervention on mental and physical out-
comes among patients receiving ARTand among those re-
ceiving hypertension treatment; these two conditions
account for most chronic care attendances in South Africa
[46]. Similarities and differences between the two trials are
described in Table 1. The main distinction is the restric-
tion of the hypertension trial to one of these districts, the
eligibility criteria for patient participants and the choice of
physical outcomes. This paper describes the trial focusing
on those on ART. A separate paper describes the trial fo-
cusing on those on hypertension treatment.
Objectives
The primary objective of the CobALT trial is to compare
the effectiveness of a scalable intervention for collaborative
care of depression by non-specialist mental health workers
with usual services on the mental and physical outcomes
in adults on lifelong ART with comorbid depression. The
two primary hypotheses are that the intervention will (1)
reduce depressive symptoms at 6 months and (2) improve
viral load suppression status at 12 months. Secondary ob-
jectives are (1) to assess the effect of the intervention on
the provision of integrated care for chronic illnesses in the
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intervention facilities from the perspective of service man-
agers and providers as well as service users and (2) to
evaluate the cost effectiveness of the intervention.
Funding and registry
This and other administrative information recom-
mended by the SPIRIT checklist [47], including the
structure, function and composition of all the trial com-
mittees, are summarised in Additional files 1 and 2 of
the web-based supplementary files (see Additional file 1
for details, Additional file 2 for the SPIRIT checklist and
Fig. 1 for the SPIRIT figure). The trial is supported
through grant 5R01MH100470-03 from the National In-
stitutes of Mental Health. The funder had no role in the
design of the trial and will not have any role in the con-
duct of the trial, analyses, interpretation or decision to
submit the results for publication.
Methods
Trial design
CobALT is a pragmatic, two-arm, parallel group, strati-
fied and cluster randomised, superiority trial set in two
health districts of the North West Province of South Af-
rica. It is a type 2 hybrid design [48], evaluating an im-
plementation strategy comprising clinical, educational
and organisational elements (Table 3) in a coherent
programme designed in collaboration with operational
managers and health providers [42]. It combines charac-
teristics of implementation (e.g. process evaluation and
quality of care indicators) and clinical effectiveness re-
search (e.g. primary health outcomes). We randomised
primary healthcare clinics with a 1:1 allocation ratio, and
will measure outcomes on individual patients. The trial
is being implemented in two phases. The site for phase 1
is the Dr Kenneth Kaunda district (20 clinics, 1000 pa-
tients), where the intervention started in 10 clinics in
April 2015 and patient recruitment commenced in April
2015. We are conducting phase 2 in the adjacent Boja-
nala district (20 clinics, 1000 patients), where the inter-
vention started in 10 clinics in April 2016 and patient
recruitment commenced in July 2016.
Setting
The two study districts are typical of rural South Africa,
where the public health sector is largely responsible for
providing care to an impoverished rural population. The
Dr Kenneth Kaunda district, named after the first presi-
dent of Zambia, has a population of 700,000–800,000
people, and Bojanala has approximately 1,500,000
people, most of whom are Setswana speaking [49]. The
main economic activities are mining and agriculture,
and the unemployment rate is one of the highest in
Table 1 Comparison of the pair of trials evaluating the intervention developed during PRIME-SA
Characteristic PRIME (Programme for Improving Mental
Health CarE-SA) Trial
CobALT (Comorbid Affective Disorders, AIDS/HIV, and
Long Term Health) Trial
Setting Dr Kenneth Kaunda district, North West Province,
South Africa
Dr Kenneth Kaunda and Bojanala districts, North
West Province, South Africa
Clinic participants 20 primary care clinics 40 primary care clinics
Patient participants Patients 18 years or older attending for hypertension
treatment with a Patient Health Questionnaire score
of 9 or more (n = 1000, 50 per clinic)
Patients 18 years or older attending for ART with a
Patient Health Questionnaire score of 9 or more
(n = 2000, 50 per clinic)
Control arm The Integrated Services Delivery Model,
which includes distribution and training in the PC101
guide
Same
Intervention arm Three additional elements:1. Clinical communications
skills training for nurse clinicians2. Supplementary
training in the mental health components of PC1013.
Clinic-based behavioural health counsellors equipped
to provide morning talks on mental health to promote
mental health literacy, manualised counselling for
depression (8 sessions, individual or group) and
adherence counselling (individual)
Same
Primary mental health outcome Response at 6 months, defined as a 50% improvement
from baseline in the Patient Health Questionnaire 9
score
Same
Primary clinical health outcome Not applicable Viral load suppression at 12 months
Duration of fieldwork April 2015 to October 2016 April 2015 to December 2017
Controlled Trials Registration
Number
NCT02425124 NCT02407691
Funding UK Department for International Development National Institutes of Mental Health, United
States of America
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Fig. 1 SPIRIT figure
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South Africa at 31.5%, above the national average of
30%. The 2013 National Antenatal Sentinel HIV Preva-
lence Survey showed that 28.2% of women attending
antenatal services in the North West province are HIV
positive compared with a national average of 29.7% [50].
ART is provided at 200 nurse-led primary care clinics
across the two districts, but resources for mental health-
care are very limited. With the exclusion of a single psy-
chiatric hospital servicing the North West Province in
the Dr Kenneth Kaunda district, there are only 1.5 psy-
chiatrists, 8 psychologists and 6 community service psy-
chologists to render services to over 2 million people
resident in the two districts. Unlike some provinces of
South Africa, there are no dedicated specialised mental
health nurses, although general primary care nurses re-
ceive some basic training in mental health. There is a
regular supply of basic psychotropic medication to pri-
mary care, but no depression counselling interventions
are routinely available.
Participants
Clinics
We considered all public sector primary care clinics pro-
viding ART across the two districts for enrolment in the
trial (Fig. 2). These clinics serve thousands of adult patients
per year (median 13,693, interquartile range 5441 to
26,952), are nurse-led and supported by ward-based out-
reach teams of community health workers introduced as
part of the re-engineering of primary care ahead of the
introduction of National Health Insurance (NHI) in South
Africa [51]. The Dr Kenneth Kaunda district is one of the
11 official districts participating in the piloting of NHI, al-
though ward-based outreach teams have also been intro-
duced in the Bojanala district. We excluded the four clinics
which participated in the formative research to develop the
intervention and pilot the data collection materials as part
of the PRIME project in the Dr Kenneth Kaunda district.
To ensure that we were able to reach individual patient re-
cruitment targets in each clinic, we enrolled the 40 largest
eligible clinics, 20 from the Dr Kenneth Kaunda district
and 20 from the Bojanala district (Fig. 3).
Patients
Inclusion criteria are age 18 years or older, receiving ART,
depressive symptoms as indicated by a total score of nine
or more on the Patient Health Questionnaire-9 (PHQ-9)
[52], and valid consent. The PHQ-9 is a 9-item measure
corresponding to the criteria upon which a diagnosis of
depressive disorders is based in the Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-IV). Items are
scored based on frequency of response ranging from 0
(‘not at all’) to 3 (‘nearly every day’) and summed assum-
ing equal weighting to yield a follow-up score of between
0 and 27. A score of between 5 and 9 is associated with
mild depression, between 10 and 14 moderate depression,
between 15 and 19 moderately severe depression, and
Fig. 2 Location of the Dr Kenneth Kaunda and Bojanala districts in relation to South Africa
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between 20 and 27 severe depression. It has been widely
used for research and clinical purposes in primary care, in-
cluding in LMICs [53–55].
As part of the preparatory work for the trial, we validated
a Setswana version of the PHQ-9 among 676 chronic care
patients in the Dr Kenneth Kaunda District, comparing the
performance of a localised version of the PHQ-9 adminis-
tered by fieldworkers to that of the Structured Clinical
Interview for DSM-IV administered by a clinical psycholo-
gist. This showed that it is a valid tool for measuring de-
pressive symptoms in the trial population [56]. However,
we showed that a threshold of 9, as opposed to the more
widely used threshold of 10, was more appropriate for de-
tecting depression in this population and so applied it to
the trial eligibility criteria. The PHQ-9 area under the re-
ceiver operator curve (AUROC) was 0.85 (95% CI 0.82–
0.88). The PHQ-9 AUROC for the sub-samples of patients
with HIV or with hypertension were comparable (0.85 and
0.86, respectively). The original and localised versions are
shown in Table 2. During the localisation and lay panel
testing process the category labels were changed from
phrases ‘not at all’ to numbers (0 days) to facilitate re-
sponse by local Setswana speakers.
In keeping with the pragmatic orientation of this trial
[57, 58], we intentionally have few exclusion criteria. We
only excluded individuals if they planned to move away
from the vicinity of the clinic in the next year and would
therefore be unable to participate in follow-up data col-
lection, or were otherwise judged unable to provide in-
formed consent because of acute medical illness or
psychosis. We did not exclude participants with active
suicidal ideation, but urgently referred them for clinical
review in both intervention and control arms.
Interventions
Control arm
The integrated chronic care programme implemented by
the Department of Health (described above) forms the
control comparison and was implemented in both inter-
vention and control clinics prior to the introduction of
Fig. 3 Flow of participants
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the study intervention. At facility level, the main inter-
ventions were the reorganisation of chronic care services
and training of clinic staff in PC101. Appointment sys-
tems and waiting rooms for communicable disease ser-
vices (HIV, tuberculosis once the intensive phase of
treatment has been completed) have been integrated
with services catering for NCDs and mental health,
resulting in a single chronic care service aimed at redu-
cing fragmentation and promoting integrated care [35].
Nurses in the control facilities are able to refer patients
identified as having depression to primary healthcare
(PHC) doctors for the initiation of antidepressants (as
they are not authorised to prescribe antidepressant med-
ications in South Africa) as well as to mental health spe-
cialists, who are limited in number. Limited specialist
psychological and psychiatric care is also available at the
district hospital.
Intervention arm
In the intervention clinics, we supplemented the training
of PHC nurse clinicians in the 12 PC101 sessions with
clinical communication skills and four additional mental
health sessions to strengthen identification and manage-
ment of depression (see Additional file 3 of web-based
supplementary material for examples of PC101 guides).
We trained facility trainers in the intervention facilities
to deliver this supplementary training material. We did
not expose facility-based trainers in the control facilities
to this supplementary training. In addition, we strength-
ened referral pathways for treatment and counselling
(see collaborative care model depicted in Fig. 4). For
treatment, we provided supplementary training of PHC
doctors in mental healthcare. For counselling, we intro-
duced lay behavioural health counsellors into the inter-
vention clinics with structured supervision from district-
based psychologists. The initial and long-term intention
was to capacitate and diversify the role of existing
facility-based lay HIV counsellors to include limited and
structured counselling for service users with mild de-
pressive symptoms, so as to ensure sustainability of the
service. However, during the formative phase it became
apparent that there were a number of scope of practice
issues that needed to be addressed at a policy level be-
fore this was feasible [42]. So as not to delay the trial,
the behavioural health counsellors were thus sponsored
from study funds for the duration of the trial. In parallel,
in order to optimize future sustainability of the interven-
tion (should it be shown to be effective), the study
Table 2 Patient Health Questionnaire-9: general and localised versions
Over the last 2 weeks, how often have you been bothered by
any of the following problems?a
Not at all Several days More than half
of the days
Nearly every day
Over the last 2 weeks, how often have you been bothered by
any of the following problems?b
0 days 1–7 days 8–11 days 12–14 days
Little interest or pleasure in doing things 0 1 2 3
Feeling down, depressed or hopeless 0 1 2 3
Trouble falling or staying asleep, or sleeping too much 0 1 2 3
Feeling tired or having little energy 0 1 2 3
Poor appetite or overeating 0 1 2 3
Feeling bad about yourself, or that you are a failure or have let
yourself or your family down
0 1 2 3
Trouble concentrating on things, such as reading the newspaper
or watching television
0 1 2 3
Moving or speaking so slowly that other people could have
noticed? Or the opposite, being so fidgety or restless that you
have been moving around a lot more than usual
0 1 2 3
Thoughts that you would be better off dead or of hurting
yourself in some way
0 1 2 3
Please could you confirm your answer for this question: Over
the last 2 weeks, how often have you been bothered by
thoughts that you would be better off dead or of hurting
yourself in some way
0 1 2 3
Total Score ___ = ___ + ___ + ___
If you checked off any problems, how difficult have these
problems made it for you to do your work, take care of things
at home, or get along with other people?a,b
Not difficult at all Somewhat difficult Very difficult Extremely difficult
aGeneral version
bLocalised version
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investigators are engaged in a number of advocacy ef-
forts with policy-makers to diversify the scope of prac-
tice of the existing lay HIV counsellors. A comparison of
the training provided in the control and intervention
clinics is contained in Table 3.
Patient-level outcomes
The co-primary patient mental and physical outcomes
are (1) PHQ-9 response at 6 months, defined as at least
a 50% improvement in PHQ-9 score compared with
baseline; and (2) viral load suppression 12 months after
patient enrolment, defined as a viral load value of < 1000
copies/mL in line with the third ‘90-90-90’ target [1].
There are multiple ways of managing the participant
level analysis metric for the PHQ-9, which we are using
both to define eligibility in this trial (score of 9 or more)
and to assess response to treatments. We have selected as
the primary outcome measure the response at 6 months,
defined as a 50% improvement from baseline score. Sec-
ondary outcome measures related to PHQ-9 include re-
sponse at 12 months; mean scores at 6 and 12 months;
remission, defined as a score of 5 or less at 12 months; and
category of severity (mild, moderate, severe) at 6 and 12
months. We record the treatment for depression, including
initiation or intensification of antidepressant medication,
referral to a counsellor for depression counselling, number
of contacts with a counsellor, and referral to a mental
Fig. 4 Collaborative care package for depression
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Table 3 Comparison of training provided to control and intervention clinics
Provider Role Training Content of training Method and timeframe
Control and intervention facilities
PHC nurses Identifies, provides
brief interventions
and refers
Basic onsite
PC101 training
Case scenarios used for training in
the identification and management
of common chronic diseases, including
communicable diseases, NCDs
(including hypertension), women’s
health and mental health. Mental
health components draw on the
WHO’s mhGAP guidelines [91] and
adopt a syndromic approach to
mental health symptoms (such as
stress, insomnia, suicidal thinking)
with diagnostic algorithms and
treatment checklists for depression
(1) PC101 Master Trainers train Facility
Trainers who train PHC nurses at the
facilities(2) Twelve weekly sessions over
12 weeks at facilities (two of which are
on mental disorders)(3) Training uses
case scenario material of patients with
chronic conditions, including comorbid
conditions
Intervention facilities
PHC nurses Identifies, provides
brief interventions
and refers
Orientation and
clinical
communication
skills training
(1) Overview of the system changes
being made by the DoH in South Africa
to accommodate the demands of
integrated chronic care; their role as case
managers within the collaborative care
model for depression(2) Orientation to
patient-centred care and clinical
communication skills necessary to
implement patient-centred care(3) Skills
to manage patient emotions within the
consultation; self-care including how to
cope with their own emotions and burn-
out(4) Motivational interviewing skills to
promote patient self-management
Four 2-h interactive workshops at PHC
facilities/regional training centre
PC101
supplementary
training in
mental health
(1) Detection of depression and anxiety,
psychoeducation and referral to
counsellors and/or doctor for
consideration of psychotropic medication
in the case of moderate severe
depression(2) Detection of risky alcohol
use and brief intervention for harmful/
hazardous drinking and for detoxification
and referral to specialists rehabilitation
programmes for dependency as per the
mhGAP guidelines [91] (3) Assessment of
suicide intent (4) Patient review after 8
weeks to assess response to treatment
and onward referral for specialist care as
indicated by the mhGAP evidence-based
guidelines for LMICs [91], if necessary
following a treatment-to-target approach
as contained in the collaborative care
model (Fig. 4); treatment to target
involves tracking a patient’s symptom
severity and adjusting or intensifying
treatment should patients not show an
improvement in symptoms following
initial treatment.
(1) PC101 Master Trainers train Facility
Trainers (2 day workshop) who train PHC
nurses at the facilities(2) Three weekly
sessions over 3 weeks at facilities, with
an additional follow-up session 1 month
later(3) Training uses case scenario
material of chronic patients with
comorbid mental disorders
PHC doctors Diagnoses, initiates
and monitors
response to
psychotropic
medication
Orientation and
training in
mhGAP/PC101
(1) Orientation to the importance of
treating comorbid depression (2) Training
in mhGAP guidelines(3) Follow-up using
case studies of patients
Three 1-day workshops spread over 6
months
Behavioural health
counsellors
Provides evidence-
based counselling
Counselling
training
(1) Manualised counselling package
comprising 8 sessions (delivered
individually or in groups) (2) Session 1:
Psycho-education session on depression;
the last session is a closure session;
Sessions 2–7 draw on problem solving
and cognitive behavioural techniques,
One week of off-site training; one week
of peer-to-peer mentoring; in vivo
supervision by a psychologist of each
session; weekly follow-up group
supervisory sessions, augmented where
possible by weekly individual supervision
sessions
Fairall et al. Trials  (2018) 19:193 Page 10 of 24
health specialist (clinical psychologist, psychiatrist or sec-
ondary care services). The Perceived Stress Scale is in-
cluded to measure the degree to which life situations are
considered stressful [59].
Secondary HIV measures are viral suppression at 12
months defined as a viral load of < 400 copies/mL, viro-
logic failure defined as two consecutive viral load values
> 1000 copies/mL, and change in viral load values over
time. Other ART-linked outcomes include programme
retention, appropriate maintenance on enrolment ART
regimen and ART regimen switched to second line, and
the Internalised AIDS Related Stigma Scale [60], which
we include to explore the relationships between stigma,
retention in care and viral load suppression.
Viral loads will be measured using venous samples in
participants at baseline and at the 12-month follow-up
interview, and the samples submitted to the National
Health Laboratory Service responsible for routine viral
load monitoring, which current ART programme guide-
lines recommend should occur annually [61]. Thus, the
majority of patients are expected to undergo both routine
programme and research viral load monitoring during the
course of the trial. Funds available for viral load monitor-
ing as part of the trial are limited and therefore only
patients with no documented programme results (in the
past 6 months) will be asked to submit a baseline research
viral load. Research-funded 12-month viral loads will be
collected on all patients as this is the primary physical
outcome.
We will also aim to collate all programme and
research-viral loads into a single longitudinal record for
every patient enrolled in the trial, through linkage with
the viral load repository at the National Health Labora-
tory Service and application of algorithms for this link-
age previously applied to province-wide ART datasets
[27]. In South Africa, detectable viremia is most com-
monly caused by non-adherence, and only rarely due to
resistant virus [62]. Thus, the proportion of participants
with a suppressed viral load provides a reasonable esti-
mate of ART adherence. In addition, we have included a
Visual Analogue Scale for self-reported adherence in the
last month as a secondary outcome measure at 12
months [63–65]. The integrated care nature of the inter-
vention, with a focus on the detection and management
of chronic diseases, and the surge in multi-morbidity in
the general population, and ART populations in particu-
lar [66], are the reasons for monitoring risk factors for
cardiovascular diseases (blood pressure, weight, smoking
Table 3 Comparison of training provided to control and intervention clinics (Continued)
Provider Role Training Content of training Method and timeframe
including behavioural activation
to address the common triggers
of depression and anxiety which,
in this population, include poverty,
interpersonal conflict, social isolation
and avoidance, grief and loss, and
stigma that emerged from qualitative
interviews held with service users
with during the formative phase of
the PRIME project in South Africa in
two provinces [92]; a prototype had
been field tested in KwaZulu-Natal
and positive results demonstrated
in an individually randomised pilot
trial [43]; adherence session
provides information on the chronic
condition(s) and chronic medication(s)
the patients may have as well as helping
patients with adherence difficulties (3)
While developed to treat depression,
the intervention has been found to
promote improvements in global
psychological functioning as well [43],
thus having the potential for
trans-diagnostic effects, in line with
evidence that diagnosis-specific
cognitive behavioural therapy has
beneficial effects on untargeted
comorbid emotional disorders [43]
Specialists(Psychologist/
psychiatrist)
Training,
supervision of
counsellors
Orientation to
task sharing
Psychologists (including interns and
community service psychologists)
orientated to their roles
Once-off workshops
DoH Department of Health, LMICs low- and middle-income countries, mhGAP WHO Mental Health Gap Action Programme, NCDs non-communicable diseases,
PC101 Primary Care 101, PHC primary healthcare
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status) and the detection and treatment of other chronic
diseases.
We will assess the provision of integrated care from a
patient perspective using the Patient Assessment of Care
for Chronic Conditions [67] at 12 months. Economic
outcomes include healthcare utilisation, productivity and
the World Health Organization’s Disability Assessment
Scale [68]. We will monitor potential harms, including
hospitalisation, death and suicide, the last two through
follow-up at clinics, linkage with the national mortality
register, and interviews with clinic staff and family mem-
bers. Table 4 provides a full list of outcomes, time of
measurement and source of data. In the section on ‘Ad-
verse events and monitoring of possible harms’ and in
Table 5, we describe in more detail outcomes reflecting
possible harms and methods used for their detection.
Health system-level outcomes
We shall assess the provision of integrated care from a
health system perspective using the Assessment of
Chronic Illness Care, which covers six areas of system
change to promote optimal chronic care (linkages to
community resources, self-management support, deci-
sion support, delivery system design, clinical information
systems and organisation of the health system) [69]. We
will complete the Assessment of Chronic Illness Care on
a sample of clinic staff from intervention and control
clinics at 12 months. In addition, we shall conduct quali-
tative process evaluation interviews with one facility
manager and one service provider from each of the
intervention clinics at 12 months to understand their
perspectives on how integrating mental health services
for depression has affected overall HIV clinical care.
Participant recruitment and timelines
We will conduct clinic recruitment in two phases. We
deem this phased approach necessary because of the
scope of the intervention support and fieldwork oper-
ation required for the trial, both of which place consid-
erable demands on the trial co-ordinating centre
operating with limited human resources and a limited
budget. The trial will start in the Dr Kenneth Kaunda
district because the intervention has been piloted in that
district and because the comparison intervention, the In-
tegrated Care Services Model, has been implemented in
the district before Bojanala because of its inclusion as
one of the NHI pilot districts. We will conduct clinic
randomisation on two separate occasions to allow for
changes in clinic operation (smaller clinics are closed or
relocated on a regular basis in South Africa) and the vol-
ume of attendances. We will factor in an embedding
period of 2 months between the start of the intervention
and recruitment of patient participants. In determining
the duration of the embedding period, we balanced the
time required to ensure the intervention was functioning
within the clinics with the likelihood that patient partici-
pants had not yet been exposed to the intervention by
the time of enrolment. Figure 3 shows the recruitment
of clinics and patient participants into the trial as well as
follow-up evaluations.
Sample size
We calculated the sample size for a superiority trial be-
cause we hypothesized that the intervention would lead
to reduced depressive symptoms for patients on ART
with comorbid depression, which would in turn posi-
tively influence their adherence to ART and care, and
improve their HIV outcomes. We based our estimates of
viral load suppression on data from our previous RCT
on task-shifting HIV care in which 70% of ART patients
had suppressed viral loads at follow-up with an intra-
clinic correlation coefficient (ICC) of 0.046 [40]. We as-
sumed that rates of viral load suppression will be slightly
lower in a group of patients suffering from depression
(65%) as it is a known risk factor for poor adherence
[18, 70]. A sample size of 2000 participants from 40
clinics (50 patients per clinic, 1000 per group) provides
80% power to detect a 10% difference in 1-year viral load
suppression at the 5% significance level assuming an
ICC of 0.04 and a 20% loss to follow-up based on a pre-
vious trial in this setting [38]. To determine the appro-
priate parameters for the PHQ-9 sample size calculation
we searched PubMed for all RCTs which had used the
PHQ-9 as an outcome. Of the 126 trials screened, we
identified nine as relevant to the design of our trial [71–
79], including four cluster trials and five individually
randomised studies. The trials used a mix of metrics, in-
cluding difference in means, response and remission
rates, measured at a range of time points. We disre-
garded several of the trials because their baseline scores
were far higher than those we had observed in our
population of interest during the validation of the
Setswana localisation of the PHQ-9. We instead based
our sample size estimates on three cluster trials com-
pleted in the Netherlands [71], Italy [77] and the UK
[79], where PHQ-9 response rates at 6 months were re-
ported and where baseline scores were similar to what
we anticipated. Only two of the five cluster trials re-
ported an ICC [71, 79] and, in one of these, it was unin-
terpretable because of very small cluster sizes [71]. We
then completed a series of calculations to determine
power to detect a difference of between 10% and 12% in
response rates at 6 months, with the number of clusters
and cluster size fixed by the viral load calculation at 40
and 50, respectively (Table 6). We allowed for the pro-
portion of those who responded in the control group to
vary between 30% and 35%, for the ICC to vary between
0.02 and 0.04 (we assumed lower ICCs were likely given
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Table 5 Defining, monitoring and reporting of harm
Type of harm Source and method of identification Action(s) to mitigate harm to
specific participants
Reporting frequency and
to whom
Adverse Events
Positive response to ninth item
of the PHQ-9: “Thoughts that
you would be better off dead
or of hurting yourself in some
way”
Participant interviews (baseline, 6-month
follow-up, 12-month follow-up)Flag within
electronic questionnaire prompting
interviewer to act
Repeat question to reduce telescoping-type
reporting errorsIf ≥ 8 days in last 2 weeks,
immediate referral to clinic staffIf between
1 and 7 days, then written educational
material given
6 monthly report to
DSMB6 monthly to IRB
(with DSMB letter of
recommendation)
PHQ-9 score of ≥ 20 at 12
months suggesting persistent
severe depression
Participant interviews (12-month follow-
up)Data report (monthly)
Summary forwarded to clinic together with
recommendations for further treatment
6 monthly report to
DSMB6 monthly to IRB
(with DSMB letter of
recommendation)
Blood pressure severely raised
(≥ 180/110) placing participant
at immediate risk of
cardiovascular event
Participant interviews (baseline, 6-month
follow-up, 12-month follow-up)Flag within
electronic questionnaire prompting
interviewer to act
Immediate referral to clinic staff for review 6 monthly report to
DSMB6 monthly to IRB
(with DSMB letter of
recommendation)
Raised blood pressure at follow-
up representing undiagnosed or
uncontrolled hypertension
Participant interviews (baseline, 6-month
follow-up, 12-month follow-up)
Longitudinal patient record
Summary forwarded to clinic together with
recommendations for further treatment
6 monthly report to
DSMB6 monthly to IRB
(with DSMB letter of
recommendation)
Detectable viral load at follow-
up representing possible
adherence problems or
treatment failure
Participant interviews (baseline, 6-month
follow-up, 12-month follow-up)Research
viral loadsRoutinely collected viral
loadsLongitudinal patient record
Summary forwarded to clinic together with
recommendations for further treatment
6 monthly report to
DSMB6 monthly to IRB
(with DSMB letter of
recommendation)
Serious Adverse Events
Significantly raised viral load
(> 1000 copies/mL) during
pregnancy placing fetus at
risk of HIV transmission
Participant interviews (baseline, 6-month
follow-up, 12-month follow-up)Research
viral loadsRoutinely collected viral
loadsData report (weekly)
Immediate notification of PI (LF) or delegate
(NF) who will personally call clinic and
follow-up with them until we can be sure
woman is back in care and appropriately
treated
Notification of IRB, DSMB
and NIMH within 7 days
of knowledge of
confirmation
Hospitalisation Participant interviews (baseline, 6-month
follow-up, 12-month follow-up)Routinely
collected hospitalisation dataData report
(monthly)
No immediate action other than 6 monthly
review by DSMB
6 monthly report to
DSMB6 monthly to IRB
(with DSMB letter of
recommendation)
Death (excluding suicide) Participant interviews (loss to follow-up
form)National population registerData
report (monthly)
No immediate action other than 6 monthly
review by DSMB
6 monthly report to
DSMB6 monthly to IRB
(with DSMB letter of
recommendation)
Death by suicide Participant interviews (loss to follow-up
form)National population register
(provided we are able to access cause
of death)Data report (weekly)
Immediate notification of PI (LF), who will
follow-up with fieldwork staff to confirm
suicide and establish date of suicide
Notification of IRB, DSMB
and NIMH within 7 days
of knowledge of
confirmed suicide
DSMB Data and Safety Monitoring Board, IRB Institutional Review Board, NIMH National Institute of Mental Health, PI principal investigator
Table 6 Power calculations for primary PHQ-9 outcome (response rate at 6 months defined as 50% improvement from baseline)
No. of clusters per
group
Cluster
size
Proportion responded
in control group
Proportion responded
in intervention group
Alpha ICC Power
(No dropout)
Power
(20% dropout)
20 50 0.30 0.40 0.05 0.04 76 73
20 50 0.30 0.40 0.05 0.02 90 87
20 50 0.30 0.42 0.05 0.04 89 87
20 50 0.30 0.42 0.05 0.02 97 96
20 50 0.35 0.45 0.05 0.02 89 87
20 50 0.35 0.47 0.05 0.02 97 95
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that the PHQ-9 is a health outcome) and for a loss to
follow-up rate of 20%. This showed that a sample of 50
patients in 40 clusters (1000 per group) yielded a power
of between 73% and 96% to detect a difference of be-
tween 10% and 12% in response rates at 6 months.
Recruitment and data collection
We conducted clinic recruitment in two phases. We ob-
tained an updated list of clinics in each district with recent
headcount data. We scrutinized the GPS co-ordinates of
the clinics to identify any clinics that might be located
next to each other and thus be at risk of contamination.
We then forwarded a cleaned-up list of eligible clinics to
the statistician, who selected the largest facilities and com-
pleted randomisation within sub-district strata. Because
clinics in South Africa sometimes close or are amalgam-
ated with others, we repeated the process for the Bojanala
clinics a few months before starting work in that district.
We split clinic recruitment evenly between the two dis-
tricts with 20 clinics from each.
Patient recruitment occurred independently of clinical
care or participation in the group psychosocial interven-
tion for depression. We adopted a pragmatic approach,
enrolling all patients who met the eligibility criteria re-
gardless of exposure to the intervention, recognising that
the detection of mental disorders and linkages to care
are pressing challenges for integration of mental health
services into primary care and that failure to account for
this in the design of the trial would limit the generalis-
ability of its findings to real-world primary care settings.
Patient participant recruitment started approximately 2
months after the training of nurses and counsellors in
the intervention clinics. Trained fieldworkers invited,
screened and enrolled patient participants in the trial
using a three-stage process as outlined in Additional file
4. First, trained fieldwork recruiters explained the study
to patients in the waiting room, inviting those attending
for chronic care services to come forward for more in-
formation if they were interested. Depression, HIV or
ART were not be mentioned during this general infor-
mation sharing so as not to single out those who wished
to participate. The recruiter completed a brief verbal
screen of patients who came forward to establish
whether or not they were on ART and whether they
planned to stay in the study area for the duration of the
following year; this was done on a one-to-one basis. Eli-
gible patients were then walked across to a fieldwork
interviewer based in a private section of the clinic where
the emotional content of the PHQ-9 instrument was ex-
plained and opt out consent sought before proceeding
with the full screen. We then sought formal consent
from patients who screened positive using the PHQ-9.
This covered permission to be interviewed at enrolment,
at the two subsequent time points, 6 and 12 months
later, determination of the participant’s viral load at en-
rolment and 12 months later, permission to review their
clinical folders and hospital records to assess quality of
care provided and healthcare utilisation, and to send re-
minders and confirmation of follow-up interviews by
text message and phone calls. We requested participants
Fig. 5 Integration of data sources into a longitudinal patient record
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to supply their national identity numbers to permit link-
age with the national population register, which records
more than 90% of all deaths in South Africa. We only
collected patient identifiers once written informed con-
sent was provided (Additional file 5). The recruitment
process for the PRIME and CobALT trials was con-
ducted as a combined process in the Dr Kenneth Ka-
unda district and patient recruitment continued until
the target of 50 patients per clinic was met for both tri-
als. We invited patients who were on both ART and an-
tihypertensive medications, and who qualified for
enrolment in the trial, to participate in both studies and
complete two sets of consent forms. Fieldwork inter-
viewers conduct interviews in one of the three local lan-
guages (Setswana, English, Afrikaans), chosen by the
participant (see Additional file 6 for the full question-
naire). Fieldwork interviewers collect data using hand-
held electronic devices, which we have previously used
in similar field work data collection exercises in South
Africa [80]. We ask participants to return to the clinic
for follow-up interviews. We send text reminders in ad-
vance of follow-up visits, and contact participants by
telephone to confirm their appointments. At follow-up,
participants undergo an interview to determine the se-
verity of their depressive symptoms, the nature of the
care they received at the clinic, including care for de-
pression and HIV, and other healthcare utilisation and
economic outcomes. Follow-up viral loads will be drawn
from all patients at 12 months.
Randomisation, allocation concealment and blinding
We randomised clinics and their patients to one of two
parallel groups, with an allocation ratio of 1:1. Within
each district, we considered the distribution of clinics
within sub-districts to ensure that we did not introduce
potential confounding through geographically deter-
mined management of clinics. Within the Dr Kenneth
Kaunda district, 12 clinics fall within the Matlosana sub-
district in the area, including and surrounding the major
town of Klerksdorp, and have been randomised as one
stratum. The remaining eight clinics are situated in more
rural areas and randomised together. Within the Boja-
nala district, 10 clinics are in the central district of Rus-
tenburg in and around the town of the same name and
are randomised in a 1:1 allocation. The remaining 10
clinics are distributed over a far wider area than in Dr
Kenneth Kaunda district and spread across the three
sub-districts of Moretele, Kgetleng River and Madibeng.
We combined two of the smaller sub-districts (Moretele
and Kgetleng River) into one, so that we have two strata
each with five clinics available for randomisation. We
randomly selected one of these strata to have three
intervention clinics to two control clinics, and vice versa
in the other stratum, so that we have 10 intervention
clinics and 10 control clinics in the Bojanala district.
The trial statistician carried out randomisation using n-
Query advisor prior to the intervention or screening of
participants for recruitment. Blinding of participants and
clinicians is not possible because it will be clear which
clinics will be implementing what interventions. The
trial statistician who carried out randomisation did not
know the characteristics of the clinics being randomised,
and the primary statistical analysis will also be blinded
to allocation status.
Data management
Interview data is uploaded as soon as questionnaires are
completed, internet connectivity permitting, and stored
in a secure SQL server at the Trial Co-ordinating Centre
at the University of Cape Town Lung Institute. We inte-
grate data from interviews with those from other sources
to create a longitudinal record for every patient partici-
pant (Fig. 5). These other sources include blood results
for the viral load samples drawn as part of the research
process as well as routinely monitored viral loads which
are collated in a central national repository. We search
hospitalisation records quarterly and integrate linkages
into the research dataset. We maintain a separate data-
base of patients referred to facility-based counsellors and
link their attendance of sessions with the trial patient
database. The research version of the national popula-
tion register, curated by the South African Medical Re-
search Council, will be linked once at the end of the
study to identify any deaths which had not already been
identified through follow-up of patients who did not re-
turn for their 6- and 12-month interviews.
Quality control measures include supervision of field-
workers, electronic alert messages for fieldworkers if un-
usually high or low values are entered into the electronic
questionnaire, automated skips, and monitoring of the
data to identify unusual values or trends. The handheld
devices used for data collection are password protected
and interview data is uploaded at the end of each inter-
view without being stored on the device. Only a small
number of data managers have access to personal identi-
fiers. Anonymised data (without names or national iden-
tity numbers) will only be provided to selected members
of the research team. Members of the research team, in-
cluding all fieldworkers and fieldwork supervisors, are
required to sign a confidentiality agreement to ensure
the protection of confidential data.
Statistical methods
We will estimate the effects of the intervention by compar-
ing the outcomes of intervention and control group pa-
tients using multiple mixed effects regression models, with
clinics as a random effect to account for the intra-cluster
correlation of outcomes. We will include the stratum as a
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covariate in the regression models, and will use Stata statis-
tical software for the analysis. All clinics and patients will
be analysed in the treatment group to which they were ran-
domly assigned. We will ascertain the completeness of
follow-up by group to evaluate the integrity of the planned
analysis. We will use binomial regression to estimate differ-
ences in proportions of patients with suppressed viral loads
and who have responded in terms of their depressive
symptoms, measured using the PHQ-9. We will analyse
secondary outcomes as follows: binomial regression for
binary outcomes, linear regression for changes in depres-
sion scores, blood pressure, weight, and waist circumfer-
ence by comparing values at follow-up adjusted for
baseline values, and Poisson regression for count outcomes
such as clinic visits and inpatient days, accounting for indi-
viduals’ duration of follow-up.
Planned secondary analyses include analysis of primary
outcomes stratified and adjusted for treatment severity,
treatment status and comorbidities at baseline. We will
also explore whether there is a differential effect among
those patients who reported receiving the counselling
intervention.
The economic evaluation will include descriptive sta-
tistics describing the health system and societal costs of
living with HIV and depression, a cost effectiveness ana-
lysis, and modelling of the intervention beyond the time-
frame of the study.
Adverse events and monitoring of possible harms
These are enumerated and defined time frames for mon-
itoring and reporting as specified in Table 5. Most guid-
ance would recognise hospitalisation, or prolongation of
hospitalisation, and death as serious adverse events, re-
quiring prompt reporting to regulatory bodies. However,
both of these events are expected to occur frequently
among adults on ART. Based on follow-up from our
previous trial in a similar ART population, we expect a
mortality rate as high as 5% during the 12-month
follow-up period, and a hospitalisation rate of approxi-
mately 10% [40]. We expect much of this mortality and
morbidity to be due to the underlying HIV infection, ad-
vanced enough to warrant treatment with ART prior to
the introduction of universal treatment. Systematic mon-
itoring of hospitalisations and deaths is planned, but will
be episodic, occurring at the 6- and 12-month follow-up
participant interviews, and with quarterly linkage of hos-
pitalisation and once-off linkage with the national popu-
lation register data. Given that these events, while
serious, are common in this population, are likely to be
related to the underlying HIV disease progression, and
that monitoring is episodic, we have proposed that the
frequency of these events be reviewed 6 monthly by the
Data and Safety Monitoring Board (DSMB), and then re-
ported to the relevant Institutional Review Boards (IRBs)
(University of Cape Town, University of Kwazulu-Natal
and King’s College London), with the DSMB Letter of
Recommendation. Because suicide may well be related
to a mental health intervention, and is likely to be rare,
we report any such events within 7 days of the know-
ledge of the event in accordance with the recommended
Standard Operating Procedures of the University of
Cape Town’s IRB. All deaths will be followed up with
clinic staff and family members to determine whether or
not they were the result of suicide.
A further serious adverse event that is unlikely to be
related to the intervention, but which may occur as a re-
sult of participation in the data collection component of
the trial, is a markedly elevated viral load in the context
of pregnancy, placing the foetus at risk of transmission.
For this reason, it will be managed as a serious adverse
event and reported to the IRB and DSMB within 7 days.
We follow-up all viral loads in excess of 1000 copies/mL
to see whether or not they appear to be reported during
pregnancy and we urgently pursue all missing viral loads
in women who report themselves to be pregnant. Once
we confirm a high viral load in a pregnant woman, we
immediately notify the clinic staff and advise them to re-
call the women urgently for clinical care and interven-
tion to limit transmission of HIV to the baby.
We report non-serious adverse events to the DSMB 6
monthly. We ask the participants who respond positively
to the ninth item of the PHQ-9 “Thoughts that you
would be better off dead or of hurting yourself in some
way” to confirm their answer and, if they indicate having
such thoughts between 1 and 7 days in the last 2 weeks,
we provide them with written educational material on
suicide prevention. If they confirm having such thoughts
for 8 days or more in the past 2 weeks, we immediately
refer them to clinic staff for review. This protocol ap-
plied to the pre-screening process even for patients who
responded positively to the ninth item of the PHQ-9 but
were otherwise not eligible for enrolment in the trial.
Likewise, we immediately refer participants with a blood
pressure of ≥ 180/110 to clinic staff for review of their
blood pressure. Once data collection is complete, we will
present a summary of adverse events to clinics together
with recommendations for further treatment. These ad-
verse events are a PHQ-9 score of ≥ 20, suggestive of se-
vere depression, raised blood pressure at follow-up
representing undiagnosed or uncontrolled hypertension,
and detectable viral load at follow-up representing pos-
sible adherence problems or treatment failure.
Cost-effectiveness economic evaluation and modelling of
long-term costs and effects
We will use the adapted Service Utilisation Questionnaire
to systematically collect resource-use data, including any
inpatient care, consultations with health providers, use of
Fairall et al. Trials  (2018) 19:193 Page 18 of 24
medications and laboratory tests, and time and travel costs
associated with service uptake. We will collect informa-
tion on the financing sources for each of the service cat-
egories to allow for an estimation of the extent of private,
out-of-pocket expenditures incurred by recruited partici-
pants and their families. The unit costs or prices of these
various resource inputs will be taken from previously con-
ducted costing studies in South Africa [81] and from
WHO-CHOICE data [82]. We will obtain medication
costs from the Primary Care Guideline App published by
the National Department of Health in South Africa [83].
Time loss from work may be affected by the interventions
and we will measure this at baseline and follow-up and
will value it using average wage rates. We will add the
above costs to those of the actual intervention, which will
be determined using an ‘Active Ingredients’ approach and
allocated to trial participants using responses derived from
the Service Utilization Questionnaire and linkage to re-
lated databases (e.g. counselling records). We will derive
these from activity data (session provided per patient) and
therapy unit costs (based on salaries, overheads and work-
ing hours). We will then make cost comparisons using
bootstrapping methods to account for likely skewness in
the data distributions.
To examine issues of cost-effectiveness, we will first re-
late estimated service costs per case in the different arms
of the trial to primary study outcomes (viral loads and
PHQ-9 scores). Based on earlier studies of stepped care
for depression in India [84], a decrease in overall resource
use can be expected due to a drop in ineffective but finan-
cially burdensome visits to providers unqualified to offer
appropriate depression care. Since health outcomes for
the stepped care intervention are also expected to improve
significantly, the intervention will ‘dominate’ usual care
(i.e. better outcomes, less cost); such a hypothesis negates
the need for a power calculation. If, however, costs are
found to be higher in the intervention group, boot-
strapped incremental cost-effectiveness ratios for PHQ-9
depression and viral load scores will be derived. Irrespect-
ive of whether point estimates demonstrate dominance,
results will be plotted on a cost-effectiveness plane and
presented as cost-effectiveness acceptability curves in
order to show the probability of the intervention being
cost-effective at a range of ‘willingness-to-pay’ threshold
levels. We will conduct sensitivity analysis to take account
of uncertainty and imprecision in the measurements, in-
cluding multiple imputation models for missing values.
As a second stage, we will move beyond the time and
space constraints of the trial and consider longer-term costs
and effects of the trial intervention at the population level.
For this, we will construct and populate a quantitative eco-
nomic model of expected lifetime costs and health gains,
based on the earlier Markov modelling studies of Bach-
mann [85] and Cleary [81], but adapted to better capture
other health states and outcomes of interest (depression
and other NCDs, in particular cardiovascular disease and
diabetes). We will convert health improvements observed
in the trial into years of healthy life gained at the population
level in the newly developed mental, neurological and sub-
stance use module of the inter-UN OneHealth strategic
planning and costing tool [86], specifically by multiplying
observed effect size for the intervention by the target rate
of treated prevalence in the population. We will similarly
compute population-level costs in OneHealth by multiply-
ing the resource use and cost per case by the number of
cases treated in the population at target coverage levels.
Process evaluation
Given the complex nature of the intervention, which in-
volves changing clinical flow and diversifying clinical
functions, we have planned an intense process evalu-
ation that is informed by the Medical Research Council
framework for process evaluation of complex interven-
tions [87]. We will use mixed methods using a combin-
ation of quantitative process variables collected across
the clusters as well as in-depth qualitative process evalu-
ation interviews.
In order to understand factors that may influence vari-
ations in the main health outcome findings between the
arms and across the clusters, we will assess both possible
contextual factors as well as factors associated with the
fidelity and quality of implementation of the interven-
tion. We will gather robust indicators on fidelity and
quality of implementation of the intervention across the
clusters through the collection of process indicators on
the following:
1) Coverage of training sessions for nurse providers in
Clinical Communication skills (intervention arm
only), basic PC101/Adult Primary Care (intervention
and control arm) and enhanced mental health
PC101 training sessions (intervention arm only);
2) The number of in vivo training sessions and
supervision received by the lay behavioural health
counsellors across the clusters;
3) The number of patients identified and referred for
depression treatment to different providers within
the collaborative care model (lay counsellor, doctor,
mental health specialist);
4) Fidelity checks on the implementation of the
counselling intervention whereby lay behavioural
health counsellors will record at least one of each of
the eight sessions. These recorded sessions will be
rated using two independent psychological
practitioners using a fidelity checklist covering
micro-counselling skills, technical skills and how
well the counsellor adheres to the steps in the
Fairall et al. Trials  (2018) 19:193 Page 19 of 24
counselling manual developed during the formative
phase of the trial;
5) The number of counselling sessions received by each
patient referred to the counsellor and who presented
themselves for counselling.
To clarify causal mechanisms and identify contextual
factors associated with variation in outcomes of the trial
in the implementation and control arms as well as across
the clusters, we will collect the following data:
1) Facility, district and community level profile data
that will record all possible contextual factors that
may influence variation in outcomes in the
intervention and control clusters such as staff
turn-over, drug stock outs, community protest
action, clinic closures.
2) We will conduct qualitative process evaluation data
through in-depth interviews post hoc on purposefully
sampled clusters informed by 6 month depression
outcome data in both the intervention and control
facilities. This will allow for more in-depth investiga-
tion of the variations between arms and clusters that
may emerge in the outcome data [88]. In-depth
qualitative process evaluation interviews will be held
with a convenience sample of service providers within
the collaborative care model as well as with service
users. For the latter, we will purposefully select
participants using a sampling frame based on process
indicators (intervention arm) and participant
interview responses (control arm) of service provider
referred to, as well as dosage of the intervention
received. These interviews will be transcribed and
translated where necessary with back translation
checks applied, and analysed using framework analysis
with the aid of NVivo 10 qualitative data analysis
software. Framework analysis was originally developed
for qualitative data analysis in applied policy analysis
research [89], and provides a systematic structure for
the analysis process, allowing for the use of a priori
and emergent codes to be used in the analysis process
and involves a number of steps, namely (1) reading
and re-reading the transcripts; (2) the development of
a coding framework based on the interview questions;
(3) coding of the data, with emergent themes being
added to the coding framework during this coding
process; (4) summarizing the responses from the
respondents across each theme; and (5) interpreting
the final themes in light of what they suggested for
service planning and interventions.
Ethics and dissemination
We obtained permission to enrol and randomise the
clinics in the trial from the relevant district and
provincial health department. We ask patients to provide
consent for data collection and not randomisation as the
clinic to which they are assigned is determined by where
they live. We use a clearly defined and phased recruit-
ment process to enrol patients in clinics (Additional file 4)
to minimise the chance of inadvertent identification of
patient participants as being HIV positive within clinic
waiting rooms, and to manage the risk of discomfort
posed by the more sensitive content of the PHQ-9 ques-
tionnaire. Fieldworkers will explain the trial information
sheets in detail to prospective patients (Additional file 5).
We specifically require patients to declare that they under-
stand the consent to be voluntary and that it can be with-
drawn at any time, to agree to the use of their personal
information for study purposes, to undergo three inter-
views (baseline, 6 and 12 months), to allow research staff
to access their medical records, and to permit future
analysis of their de-identified data provided such analyses
are reviewed and approved by a research ethics commit-
tee. Patient level data will be made available from the
corresponding author at lara.fairall@uct.ac.za at the time
of publication of the main trial results. Consent for data
sharing will not be explicitly specified in the consent
process but the presented data will be anonymised and
risk of identification is low.
Ethical approval for the trial was obtained from the Uni-
versity of Cape Town Human Research Ethics Committee
(reference number 211/2013), King’s College London Re-
search Ethics Office (reference number PNM/12/13-159),
the University of Kwazulu-Natal Biomedical Research Eth-
ics Committee (reference 211/2013), and the North West
Provincial Department of Health.
We will first submit the results of the trial for peer-
review publication within 1 year of the last patient being
followed-up. We will acknowledge substantive contribu-
tions to the design, conduct, analysis and interpretation
of the trial through co-authorship and criteria for contri-
butorship specified by the International Committee of
Medical Journal Editors will be applied [90]. We have
planned separate publications to document the interven-
tion, and the economic and process evaluations. We will
feed back the results to the district and provincial health
departments through a series of local workshops at dis-
trict and provincial level. They will be disseminated and
debated with the South African National Department of
Health through the Project Steering Committee (for
composition see Additional file 1). Policy briefs and a
video summary will be used to disseminate results to a
wider audience.
Discussion
The overall purpose of the CobALT trial is to provide evi-
dence on the effectiveness and cost-effectiveness of scalable
interventions to reduce the treatment gap posed by the
Fairall et al. Trials  (2018) 19:193 Page 20 of 24
growing burden of depression among adults on lifelong
ART. Specifically, the trial is testing the effectiveness of a
health systems intervention, based on a localisation of the
World Health Organization’s Mental Health Gap Action
Programme guidelines, integrated into an existing, tested
and scaled-up training programme to strengthen nurse-led
primary care. This approach uses a collaborative care
model led by nurses, and complemented by referral ser-
vices to primary healthcare doctors and clinic-based behav-
ioural health counsellors using a manualised depression
counselling intervention. The trial design is a large prag-
matic trial conducted in 40 nurse-led primary care clinics
across two rural districts of South Africa with outcomes
measured on 2000 adults on ART who have screened posi-
tive for depression. It will provide definitive evidence of the
effect of the intervention on mental and physical outcomes
and highlight the importance of addressing the mental
health needs in securing and sustaining the gains made by
the scale-up of ART programmes.
Trial status
Follow-up interviews are complete in the Dr Kenneth
Kaunda district and are in progress in the Bojanala district.
Additional files
Additional file 1: Administration file. (DOCX 40 kb)
Additional file 2: SPIRIT 2013 Checklist. (DOC 125 kb)
Additional file 3: PC2101 pages. (DOCX 23277 kb)
Additional file 4: Pre-consent processes. (DOCX 41 kb)
Additional file 5: Consent forms. (DOCX 492 kb)
Additional file 6: Baseline questionnaire. (PDF 7265 kb)
Abbreviations
ART: Antiretroviral treatment; CobALT: Comorbid Affective Disorders, AIDS/HIV,
and Long Term Health; DSMB: Data and Safety Monitoring Board; DSM-
IV: Diagnostic and Statistical Manual of Mental Disorders; ICC: Intraclass
correlation coefficient; ICSM: Integrated Clinical Services Management;
IRB: Institutional Review Board; LMICs: Low- and middle-income countries;
NCDs: Non-communicable diseases; NHI: National Health Insurance;
PC101: Primary Care 101; PHC: Primary healthcare; PHQ-9: Patient Health
Questionnaire; PRIME: Programme for Improving Mental Health Care;
RCT: Randomised controlled trial; STIs: Sexually transmitted infections
Acknowledgements
The authors thank the pilot and intervention clinic nurses and counsellors
who were willing to take on additional clinical responsibilities despite their
tremendous workloads, doctors and clinic managers at the study facilities,
the North West Provincial Department of Health, and the North West district
management. We thank Martin Prince, Shekhar Saxena and Ezra Susser for
their contributions to the proposal.
Funding
The primary grant is funded by National Institutes of Mental Health, United States
of America, grant number 1R01MH100470-01. In addition, GT is supported by the
National Institute for Health Research (NIHR) Collaboration for Leadership in Applied
Health Research and Care South London at King’s College London Foundation
Trust. The views expressed are those of the author(s) and not necessarily those of
the NHS, the NIHR or the Department of Health. GT acknowledges financial support
from the Department of Health via the NIHR Biomedical Research Centre and
Dementia Unit awarded to South London and Maudsley NHS Foundation Trust in
partnership with King’s College London and King’s College Hospital NHS Founda-
tion Trust. GT is supported by the European Union Seventh Framework Programme
(FP7/2007-2013) Emerald project.
Availability of data and materials
The data analysed during the current study will be made publicly available.
Authors’ contributions
LF, IP, GT, NF, AB, CLom, MB, CLun, TG, NL, DC, PM, JHH, BZ and SC participated
in designing the study; LF, IP, GT, NF, AB, CLom, MB, CLun, TG, NL, DC, PM, and
JHH participated in applying for funding; IP, LF, AB, GT, OS, DGP, RP, NM, TK and
NF participated in developing, piloting and implementing the intervention; LF,
NF, IP, AB, GT, OS, BZ and DGP participated in planning the data collection; all
authors approved the final manuscript. CobALT research team contributors are
listed in Additional file 1.
Ethics approval and consent to participate
Ethical approval for the trial was obtained from the University of Cape Town
Human Research Ethics Committee (reference number 211/2013), King’s College
London Research Ethics Office (reference number PNM/12/13-159), the University
of Kwazulu-Natal Biomedical Research Ethics Committee (reference 211/2013), and
the North West Provincial Department of Health. Patients were asked to provide
written informed consent prior to enrolment in the study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Knowledge Translation Unit, University of Cape Town Lung Institute, Cape
Town, South Africa. 2Centre for Rural Health, School of Nursing and Public
Health, University of KwaZulu-Natal, Durban, South Africa. 3Health Systems
Research Unit, South African Medical Research Council, Durban, South Africa.
4Biostatistics Unit, South African Medical Research Council, Cape Town, South
Africa. 5School of Public Health and Family Medicine, University of Cape
Town, Cape Town, South Africa. 6Department of Population Health and
Primary Care, Norwich Medical School, University of East Anglia, Norwich,
United Kingdom. 7Alan J Flisher Centre for Public Mental Health, Department
of Psychiatry and Mental Health, University of Cape Town, Cape Town, South
Africa. 8Centre for Global Mental Health, Institute of Psychiatry, Psychology
and Neuroscience, King′s College London, London, United Kingdom. 9HIV
Prevention Research Unit, South African Medical Research Cuncil, Durban,
South Africa. 10School of Health Sciences, University of KwaZulu-Natal,
Durban, South Africa. 11World Health Organization Regional Office for
Europe, Copenhagen, Denmark. 12King’s Health Economics, Institute of
Psychiatry, Psychology & Neuroscience, King’s College London, London,
United Kingdom. 13Department of Molecular Medicine and Haematology,
University of the Witwatersrand, National Health Laboratory Service,
Johannesburg, South Africa. 14Cardiovascular Medicine, Brigham & Women’s
Hospital, Boston, USA. 15Department of Medicine, University of Cape Town,
Cape Town, South Africa.
Received: 8 February 2017 Accepted: 2 February 2018
References
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90: An
ambitious treatment target to help end the AIDS epidemic. http://www.
unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed 16
Aug 2016.
2. Walensky RP, Borre ED, Bekker L-G, Resch SC, Hyle EP, Wood R, et al. The
anticipated clinical and economic effects of 90-90-90 in South Africa. Ann
Intern Med. 2016;165(5):325–33.
Fairall et al. Trials  (2018) 19:193 Page 21 of 24
3. Dellar R, Karim QA. Understanding and responding to HIV risk in young South
African women: Clinical perspectives. South Afr Med J. 2015;105(11):952.
4. Baxter C, Abdool KS. Combination HIV prevention options for young
women in Africa. Afr J AIDS Res AJAR. 2016;15(2):109–21.
5. World Health Organization. Consolidated Guidelines on the Use of
Antiretroviral Drugs for Treating and Preventing HIV Infection:
Recommendations for a Public Health Approach, Second Edition. 2016.
http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf.
Accessed 16 Aug 2016.
6. Joseph Davey D, Myer L, Bukusi E, Ramogola-Masire D, Kilembe W, Klausner
JD. Integrating human immunodeficiency virus and reproductive, maternal
and child, and tuberculosis health services within national health systems.
Curr HIV/AIDS Rep. 2016;13(3):170–6.
7. Quiros-Roldan E, Raffetti E, Focà E, Brianese N, Ferraresi A, Paraninfo G, et al.
Incidence of cardiovascular events in HIV-positive patients compared to
general population over the last decade: a population-based study from
2000 to 2012. AIDS Care. 2016;20:1–8.
8. Okeke NL, Davy T, Eron JJ, Napravnik S. Hypertension among HIV-infected
patients in clinical care, 1996-2013. Clin Infect Dis. 2016;63(2):242–8.
9. Arseniou S, Arvaniti A, Samakouri M. HIV infection and depression.
Psychiatry Clin Neurosci. 2014;68(2):96–109.
10. Sikkema KJ, Dennis AC, Watt MH, Choi KW, Yemeke TT, Joska JA. Improving
mental health among people living with HIV: a review of intervention trials
in low- and middle-income countries. Glob Ment Health Camb Engl. 2015;2
11. GBD 2013 DALYs and HALE Collaborators, Murray CJ, Barber RM, Foreman
KJ, Abbasoglu Ozgoren A, Abd-Allah F, et al. Global, regional, and national
disability-adjusted life years (DALYs) for 306 diseases and injuries and
healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the
epidemiological transition. Lancet. 2015;386(10009):2145–91.
12. Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental
illness. Lancet Psychiatry. 2016;3(2):171–8.
13. Eller LS. Depressive symptoms in HIV disease. Nurs Clin North Am. 2006;
41(3):437–53.
14. Bottonari KA, Safren SA, McQuaid JR, Hsiao C-B, Roberts JE. A longitudinal
investigation of the impact of life stress on HIV treatment adherence. J
Behav Med. 2010;33(6):486–95.
15. Leserman J, Pence BW, Whetten K, Mugavero MJ, Thielman NM, Swartz MS,
et al. Relation of lifetime trauma and depressive symptoms to mortality in
HIV. Am J Psychiatry. 2007;164(11):1707–13.
16. Beaglehole R, Epping-Jordan J, Patel V, Chopra M, Ebrahim S, Kidd M, et al.
Improving the prevention and management of chronic disease in low-
income and middle-income countries: a priority for primary health care.
Lancet. 2008;372(9642):940–9.
17. Chibanda D, Mesu P, Kajawu L, Cowan F, Araya R, Abas MA. Problem-solving
therapy for depression and common mental disorders in Zimbabwe: piloting a
task-shifting primary mental health care intervention in a population with a
high prevalence of people living with HIV. BMC Public Health. 2011;11:828.
18. Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, et al.
Depression, alcohol use and adherence to antiretroviral therapy in sub-
Saharan Africa: a systematic review. AIDS Behav. 2012;16(8):2101–18.
19. Gaynes BN, Pence BW, Atashili J, O’Donnell JK, Njamnshi AK, Tabenyang ME,
et al. Changes in HIV outcomes following depression care in a resource-
limited setting: results from a pilot study in Bamenda. Cameroon. PloS One.
2015;10(10):e0140001.
20. Sin NL, DiMatteo MR. Depression treatment enhances adherence to
antiretroviral therapy: a meta-analysis. Ann Behav Med. 2014;47(3):259–69.
21. Abdool Karim SS, Churchyard GJ, Karim QA, Lawn SD. HIV infection and
tuberculosis in South Africa: an urgent need to escalate the public health
response. Lancet. 2009;374(9693):921–33.
22. UNAIDS. UNAIDS AIDS info Country factsheets South Africa 2015.
http://aidsinfo.unaids.org/. Accessed 22 Sep 2016.
23. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al.
Outcomes after two years of providing antiretroviral treatment in
Khayelitsha, South Africa. AIDS. 2004;18(6):887–95.
24. Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates
and predictors of failure of first-line antiretroviral therapy and switch to
second-line ART in South Africa. J Acquir Immune Defic Syndr. 2012;60(4):
428–37.
25. Stinson K, Goemaere E, Coetzee D, van Cutsem G, Hilderbrand K, Osler M, et al.
Cohort profile: the Khayelitsha antiretroviral programme, Cape Town. South
Africa. Int J Epidemiol. 2017;46(2):e21.
26. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, et
al. Seven-year experience of a primary care antiretroviral treatment
programme in Khayelitsha, South Africa. AIDS. 2010;24(4):563–72.
27. South African Department of Health. Analysis of Big Data for Better
Targeting of ART Adherence Strategies: Spatial Clustering Analysis of Viral
Load Suppression by South African Province, District, Sub-district and
Facility (April 2014 - March 2015). 2015. https://openknowledge.worldbank.
org/handle/10986/25399. Accessed 16 Aug 2016.
28. South African Department of Health. Adherence Guidelines for HIV, TB and
NCDs: Policy, Service and Delivery Guidelines for Linkage to Care,
Adherence to Treatment and Retention in Care. February 2016. https://
www.nacosa.org.za/wp-content/uploads/2016/11/Integrated-Adherence-
Guidelines-NDOH.pdf. Accessed 16 Aug 2016.
29. Herman AA, Stein DJ, Seedat S, Heeringa SG, Moomal H, Williams DR. The South
African Stress and Health (SASH) study: 12-month and lifetime prevalence of
common mental disorders. South Afr Med J. 2009;99(5 Pt 2):339–44.
30. Tomlinson M, Grimsrud AT, Stein DJ, Williams DR, Myer L. The epidemiology
of major depression in South Africa: results from the South African stress
and health study. South Afr Med J. 2009;99(5 Pt 2):367–73.
31. Williams DR, Herman A, Stein DJ, Heeringa SG, Jackson PB, Moomal H, et al.
Twelve-month mental disorders in South Africa: prevalence, service use and
demographic correlates in the population-based South African Stress and
Health Study. Psychol Med. 2008;38(2):211–20.
32. Folb N, Timmerman V, Levitt NS, Steyn K, Bachmann MO, Lund C, et al.
Multimorbidity, control and treatment of noncommunicable diseases
among primary healthcare attenders in the Western Cape, South Africa.
South Afr Med J. 2015;105(8):642–7.
33. Department of Health. National Mental Health Policy Framework and
Strategic plan 2013-2020. Pretoria: Department of Health; 2013.
34. South African National Department of Health. Ideal Clinic Manual 1 April 2016.
Department of Health, South Africa. https://www.idealclinic.org.za/docs/2016/
Ideal%20Clinic%20Manual%20v16%20-%2023Jun16.pdf. Accessed 26 Sep 2016.
35. Mahomed OH, Asmall S, Freeman M. An integrated chronic disease
management model: a diagonal approach to health system strengthening
in South Africa. J Health Care Poor Underserved. 2014;25(4):1723–9.
36. Mahomed OH, Asmall S. Development and implementation of an
integrated chronic disease model in South Africa: lessons in the
management of change through improving the quality of clinical practice.
Int J Integr Care. 2015;15:e038.
37. Fairall L, Bateman E, Cornick R, Faris G, Timmerman V, Folb N, et al.
Innovating to improve primary care in less developed countries: towards a
global model. BMJ Innov. 2015;1(4):196–203.
38. Fairall LR, Zwarenstein M, Bateman ED, Bachmann M, Lombard C, Majara BP,
et al. Effect of educational outreach to nurses on tuberculosis case
detection and primary care of respiratory illness: pragmatic cluster
randomised controlled trial. BMJ. 2005;331(7519):750–4.
39. Zwarenstein M, Fairall LR, Lombard C, Mayers P, Bheekie A, English RG, et al.
Outreach education for integration of HIV/AIDS care, antiretroviral
treatment, and tuberculosis care in primary care clinics in South Africa:
PALSA PLUS pragmatic cluster randomised trial. BMJ. 2011;342:d2022.
40. Fairall L, Bachmann MO, Lombard C, Timmerman V, Uebel K, Zwarenstein M,
et al. Task shifting of antiretroviral treatment from doctors to primary-care
nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised
trial. Lancet. 2012;380(9845):889–98.
41. Lund C, Tomlinson M, De Silva M, Fekadu A, Shidhaye R, Jordans M, et al.
PRIME: a programme to reduce the treatment gap for mental disorders in
five low- and middle-income countries. PLoS Med. 2012;9(12):e1001359.
42. Petersen I, Fairall L, Bhana A, Kathree T, Selohilwe O, Brooke-Sumner C, et al.
Integrating mental health into chronic care in South Africa: the
development of a district mental healthcare plan. Br J Psychiatry J Ment Sci.
2016;208(Suppl 56):s29–39.
43. Petersen I, Hanass Hancock J, Bhana A, Govender K. A group-based
counselling intervention for depression comorbid with HIV/AIDS using a
task shifting approach in South Africa: a randomized controlled pilot study.
J Affect Disord. 2014;158:78–84.
44. Semrau M, Evans-Lacko S, Alem A, Ayuso-Mateos JL, Chisholm D, Gureje O,
et al. Strengthening mental health systems in low- and middle-income
countries: the Emerald programme. BMC Med. 2015;13:79.
45. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P,
Spiegelhalter D, et al. Framework for design and evaluation of complex
interventions to improve health. BMJ. 2000;321(7262):694–6.
Fairall et al. Trials  (2018) 19:193 Page 22 of 24
46. Mash B, Fairall L, Adejayan O, Ikpefan O, Kumari J, Mathee S, et al. A
morbidity survey of South African primary care. PLoS One. 2012;7(3):e32358.
47. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al.
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
trials. BMJ. 2013;346:e7586.
48. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-
implementation hybrid designs: combining elements of clinical
effectiveness and implementation research to enhance public health
impact. Med Care. 2012;50(3):217–26.
49. Statistics South Africa. Census 2011 Provincial Profile: North West. http://
www.statssa.gov.za/publications/Report-03-01-75/Report-03-01-752011.pdf.
Accessed 16 Aug 2016.
50. National Department of Health, South Africa. The 2013 National Antenatal
Sentinel HIV prevalence Survey, South Africa, 2013. https://www.health-e.
org.za/wp-content/uploads/2016/03/Dept-Health-HIV-High-Res-7102015.pdf.
Accessed 16 Aug 2016.
51. South African Department of Health. National Health Insurance in South
Africa: Policy Paper. 2011. http://www.gov.za/sites/www.gov.za/files/
nationalhealthinsurance.pdf. Accessed 17 Aug 2016.
52. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression
severity measure. J Gen Intern Med. 2001;16(9):606–13.
53. Monahan PO, Shacham E, Reece M, Kroenke K, Ong’or WO, Omollo O, et al.
Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults
living with HIV/AIDS in western Kenya. J Gen Intern Med. 2009;24(2):189–97.
54. Wagner GJ, Holloway I, Ghosh-Dastidar B, Kityo C, Mugyenyi P. Understanding
the influence of depression on self-efficacy, work status and condom use
among HIV clients in Uganda. J Psychosom Res. 2011;70(5):440–8.
55. Clarke TR, Gibson RC, Barrow G, Abel WD, Barton EN. Depression among
persons attending a HIV/AIDS outpatient clinic in Kingston. Jamaica. West
Indian Med J. 2010;59(4):369–73.
56. Bhana A, Rathod SD, Selohilwe O, Kathree T, Petersen I. The validity of
the Patient Health Questionnaire for screening depression in chronic
care patients in primary health care in South Africa. BMC Psychiatry.
2015;15:118.
57. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG,
et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a
tool to help trial designers. J Clin Epidemiol. 2009;62(5):464–75.
58. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M.
The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;
350:h2147.
59. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J
Health Soc Behav. 1983;24(4):385–96.
60. Kalichman SC, Simbayi LC, Cloete A, Mthembu PP, Mkhonta RN, Ginindza T.
Measuring AIDS stigmas in people living with HIV/AIDS: the Internalized
AIDS-Related Stigma Scale. AIDS Care. 2009;21(1):87–93.
61. National Department of Health of South Africa. National Consolidated
Guidelines for the Prevention of Mother-to-Child Transmission of HIV
(PMTCT) and the Management of HIV in Children, Adolescents and Adults.
April 2015. https://aidsfree.usaid.gov/sites/default/files/tx_south-africa_
pmtct_2015.pdf. Accessed 16 Aug 2016.
62. Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, et al. Virologic
failure of protease inhibitor-based second-line antiretroviral therapy without
resistance in a large HIV treatment program in South Africa. PLoS One.
2012;7(3):e32144.
63. Kalichman SC, Cain D, Fuhrel A, Eaton L, Di Fonzo K, Ertl T. Assessing
medication adherence self-efficacy among low-literacy patients: development
of a pictographic visual analogue scale. Health Educ Res. 2005;20(1):24–35.
64. Kalichman SC, Amaral CM, Swetzes C, Jones M, Macy R, Kalichman MO, et al.
A simple single-item rating scale to measure medication adherence: further
evidence for convergent validity. J Int Assoc Physicians AIDS Care (Chic).
2009;8(6):367–74.
65. Finitsis DJ, Pellowski JA, Huedo-Medina TB, Fox MC, Kalichman SC.
Visual analogue scale (VAS) measurement of antiretroviral adherence in
people living with HIV (PLWH): a meta-analysis. J Behav Med. 2016;
39(6):1043–55.
66. Oni T, Youngblood E, Boulle A, McGrath N, Wilkinson RJ, Levitt NS. Patterns
of HIV, TB, and non-communicable disease multi-morbidity in peri-urban
South Africa- a cross sectional study. BMC Infect Dis. 2015;15:20.
67. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM.
Development and validation of the Patient Assessment of Chronic Illness
Care (PACIC). Med Care. 2005;43(5):436–44.
68. Garin O, Ayuso-Mateos JL, Almansa J, Nieto M, Chatterji S, Vilagut G, et al.
Validation of the “World Health Organization Disability Assessment
Schedule, WHODAS-2” in patients with chronic diseases. Health Qual Life
Outcomes. 2010;8:51.
69. Bonomi AE, Wagner EH, Glasgow RE, VonKorff M. Assessment of chronic
illness care (ACIC): a practical tool to measure quality improvement. Health
Serv Res. 2002;37(3):791–820.
70. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression,
chronic diseases, and decrements in health: results from the World Health
Surveys. Lancet. 2007;370(9590):851–8.
71. Huijbregts KML, de Jong FJ, van Marwijk HWJ, Beekman ATF, Adèr HJ, Hakkaart-
van Roijen L, et al. A target-driven collaborative care model for Major Depressive
Disorder is effective in primary care in the Netherlands. A randomized clinical trial
from the depression initiative. J Affect Disord. 2013;146(3):328–37.
72. Gensichen J, von Korff M, Peitz M, Muth C, Beyer M, Güthlin C, et al. Case
management for depression by health care assistants in small primary care
practices: a cluster randomized trial. Ann Intern Med. 2009;151(6):369–78.
73. Ell K, Katon W, Xie B, Lee P-J, Kapetanovic S, Guterman J, et al. One-year
postcollaborative depression care trial outcomes among predominantly
Hispanic diabetes safety net patients. Gen Hosp Psychiatry. 2011;33(5):436–42.
74. Ell K, Xie B, Quon B, Quinn DI, Dwight-Johnson M, Lee P-J. Randomized
controlled trial of collaborative care management of depression among
low-income patients with cancer. J Clin Oncol. 2008;26(27):4488–96.
75. Berghöfer A, Hartwich A, Bauer M, Unützer J, Willich SN, Pfennig A. Efficacy
of a systematic depression management program in high utilizers of
primary care: a randomized trial. BMC Health Serv Res. 2012;12:298.
76. Bogner HR, Morales KH, de Vries HF, Cappola AR. Integrated management of
type 2 diabetes mellitus and depression treatment to improve medication
adherence: a randomized controlled trial. Ann Fam Med. 2012;10(1):15–22.
77. Menchetti M, Sighinolfi C, Di Michele V, Peloso P, Nespeca C, Bandieri PV, et al.
Effectiveness of collaborative care for depression in Italy. A randomized
controlled trial. Gen Hosp Psychiatry. 2013;35(6):579–86.
78. Mohr DC, Ho J, Duffecy J, Reifler D, Sokol L, Burns MN, et al. Effect of
telephone-administered vs face-to-face cognitive behavioral therapy on
adherence to therapy and depression outcomes among primary care
patients: a randomized trial. JAMA. 2012;307(21):2278–85.
79. Richards DA, Bower P, Chew-Graham C, Gask L, Lovell K, Cape J, et al.
Clinical effectiveness and cost-effectiveness of collaborative care for
depression in UK primary care (CADET): a cluster randomised controlled
trial. Health Technol Assess. 2016;20(14):1–192.
80. Seebregts CJ, Zwarenstein M, Mathews C, Fairall L, Flisher AJ, Seebregts C,
et al. Handheld computers for survey and trial data collection in resource-
poor settings: development and evaluation of PDACT, a Palm Pilot
interviewing system. Int J Med Inf. 2009;78(11):721–31.
81. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral
treatment in Khayelitsha. South Africa–a primary data analysis. Cost Eff
Resour Alloc. 2006;4:20.
82. World Health Organization. Choosing Interventions that are Cost Effective
(WHO-CHOICE). http://www.who.int/choice/country/country_specific/en/.
Accessed 26 Sept 2016.
83. South African National Department of Health. App: Primary Health Care
Clinical Guide. December 2015. https://www.health-e.org.za/2015/12/17/
app-primary-health-care-clinical-guide/. Accessed 2 Feb 2017.
84. Buttorff C, Hock RS, Weiss HA, Naik S, Araya R, Kirkwood BR, et al. Economic
evaluation of a task-shifting intervention for common mental disorders in
India. Bull World Health Organ. 2012;90(11):813–21.
85. Effectiveness BMO. cost effectiveness of early and late prevention of HIV/
AIDS progression with antiretrovirals or antibiotics in Southern African
adults. AIDS Care. 2006;18(2):109–20.
86. Chisholm D, Heslin M, Docrat S, Nanda S, Shidhaye R, Upadhaya N, et al.
Scaling-up services for psychosis, depression and epilepsy in sub-Saharan
Africa and South Asia: development and application of a mental health
systems planning tool (OneHealth). Epidemiol Psychiatr Sci. 2016;19:1–11.
87. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process
evaluation of complex interventions: Medical Research Council guidance.
BMJ. 2015;350:h1258.
88. Grant A, Treweek S, Dreischulte T, Foy R, Guthrie B. Process evaluations for
cluster-randomised trials of complex interventions: a proposed framework
for design and reporting. Trials. 2013;14:15.
89. Bryman A, Burgess RG. Analysing Qualitative Data. London: Routledge; 1994.
p. 173–94.
Fairall et al. Trials  (2018) 19:193 Page 23 of 24
90. International Committee of Medical Journal Editors. Defining the Role of
Authors and Contributors. http://www.icmje.org/recommendations/
browse/roles-and-responsibilities/defining-the-role-of-authors-and-
contributors.html. Accessed 2 Feb 2017.
91. World Health Organization. Mental Health Gap Action Programme (mhGAP)
2010. http://www.who.int/mental_health/mhgap/en/. Accessed 21 Feb 2018.
92. Petersen I, Hanass Hancock J, Bhana A, Govender K. Closing the treatment
gap for depression co-morbid with HIV in South Africa: Voices of afflicted
women. Health. 2013;5(3A):557–66.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Fairall et al. Trials  (2018) 19:193 Page 24 of 24
